文献速递肾癌与肾肿瘤

纳武利尤单抗治疗晚期肾细胞癌的成本效果分析

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2017-08-12

该研究采用马尔可夫模型,从美国支付方视角比较纳武利尤单抗与依维莫司及安慰剂二线治疗晚期肾细胞癌的成本效果。纳武利尤单抗较依维莫司每例患者平均总成本为101 070美元 vs 50 935美元,增量成本效果比为146 532美元/质量调整生命年;在100 000至150 000美元/质量调整生命年的支付意愿阈值下,纳武利尤单抗较依维莫司具有成本效果,但较安慰剂不具有成本效果。

要点

  • 纳武利尤单抗较依维莫司每例患者平均总成本为101 070美元 vs 50 935美元。
  • 纳武利尤单抗较依维莫司增加0.24生命年(0.34质量调整生命年)。
  • 在100 000至150 000美元/质量调整生命年阈值下,纳武利尤单抗较依维莫司有成本效果,较安慰剂无成本效果。

核心结论

  • 在100 000至150 000美元/质量调整生命年的支付意愿阈值下,纳武利尤单抗较依维莫司估计具有成本效果,但较安慰剂不具有成本效果。

研究设计与样本

  • 研究采用马尔可夫模型,从美国支付方视角比较纳武利尤单抗与依维莫司及安慰剂二线治疗晚期肾细胞癌的成本与效果,健康结局以生命年和质量调整生命年衡量,药物成本基于2016年Medicare报销费率。

主要发现

  • 每例患者平均总成本纳武利尤单抗为101 070美元,依维莫司为50 935美元。
  • 纳武利尤单抗较依维莫司增加0.24生命年(0.34质量调整生命年)。
  • 纳武利尤单抗较依维莫司的增量成本效果比为146 532美元/质量调整生命年,较安慰剂为226 197美元/质量调整生命年。
  • 将纳武利尤单抗最大治疗时长限制为2年,较依维莫司的增量成本效果比降至121 788美元/质量调整生命年。

关键数值与推荐

  • 增量成本效果比:纳武利尤单抗较依维莫司为146 532美元/质量调整生命年,较安慰剂为226 197美元/质量调整生命年。
  • 最大治疗时长限制为2年时,纳武利尤单抗较依维莫司的增量成本效果比为121 788美元/质量调整生命年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 分析受数据可得性和作者假设的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, new drugs have been introduced for second-line treatment of advanced renal cell carcinoma (RCC). Nivolumab increases overall survival and is associated with less toxicity compared to everolimus in this setting according to the CheckMate 025 study. However, because of the high cost of nivolumab, there is a need to define its value by considering both efficacy and cost. OBJECTIVE: To estimate the cost effectiveness of nivolumab for second-line treatment of advanced RCC from the US payer perspective. DESIGN, SETTING, AND PARTICIPANTS: A Markov model was developed to compare the costs and effectiveness of nivolumab with those of everolimus and placebo in second-line treatment of advanced RCC. Health outcomes were measured in life-years (LYs) and quality-adjusted LYs (QALYs). Drug costs were based on 2016 Medicare reimbursement rates. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Model robustness was assessed in univariable and probabilistic sensitivity analyses. We addressed the issue of the extensive duration of immunotherapy treatment among long-term survivors, which may or may not be approved by payers. RESULTS AND LIMITATIONS: The total mean cost per patient was $101 070 for nivolumab and $50 935 for everolimus. Nivolumab generated a gain of 0.24 LYs (0.34 QALYs) compared to everolimus. The incremental cost-effectiveness ratio (ICER) for nivolumab was $146 532/QALY versus everolimus and $226 197/QALY versus placebo. Limiting the maximal treatment duration of nivolumab to 2 yr reduced the ICER to $121 788/QALY versus everolimus. The analysis is limited by data availability and our assumptions. CONCLUSIONS: Our analysis established that with a willingness-to-pay threshold of $100 000 to $150 000 per QALY, nivolumab is estimated to be cost-effective versus everolimus, but not cost-effective versus placebo. PATIENT SUMMARY: We assessed the cost effectiveness of nivolumab in previously treated metastatic kidney cancer. In the USA, it would cost $146 532 to gain one quality-adjusted life-year with nivolumab versus everolimus, or $226 197 versus placebo. Nivolumab is considered cost-effective versus everolimus, but not versus placebo.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sarfaty M, Leshno M, Gordon N, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. 2017. PMID: 28807351. doi:10.1016/j.eururo.2017.07.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。